For the first time, people considering a GLP-1 medication for weight loss can choose between two different oral options instead of defaulting to an injection. Foundayo (orforglipron), approved by the FDA on April 1, 2026, and the Wegovy pill (oral semaglutide 25 mg), approved December 22, 2025, are both taken as a daily tablet — but that’s largely where the similarities end. They’re built on different molecular platforms, dosed under different rules, and priced very differently depending on your insurance.
This guide walks through the head-to-head evidence on efficacy, convenience, cost, and mechanism so you can have a more informed conversation with your healthcare provider. As your complete GLP-1 resource — injections and pills alike — WeightLossInjections.com compiled this comparison directly from FDA labeling and pivotal trial data.
Key Takeaways
- Foundayo (orforglipron) showed 14.7-16.9% mean weight loss at 52 weeks in the ATTAIN-1 trial, with some analyses citing 11.2% over 72 weeks; the Wegovy pill showed ~16.6% mean weight loss at 64 weeks in OASIS 4.
- Foundayo requires no fasting or water restrictions — it can be taken any time of day, with or without food. The Wegovy pill must be taken in the morning, on an empty stomach, with no more than 4 oz of water, followed by a 30-minute wait.
- Foundayo is a small-molecule (non-peptide) GLP-1 receptor agonist; the Wegovy pill is a peptide (semaglutide) stabilized with an absorption enhancer.
- Cost differs sharply: Foundayo can run $25/month with insurance or $149-349/month self-pay, while the Wegovy pill lists around $1,349/month before savings programs.
- Neither drug is “better” in an absolute sense — the right choice depends on your priorities around efficacy, daily routine, and cost, which is a conversation for your healthcare provider.
Foundayo vs Wegovy Pill: At a Glance
| Factor | Foundayo (orforglipron) | Wegovy Pill (oral semaglutide 25 mg) |
|---|---|---|
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA approval | April 1, 2026 | December 22, 2025 |
| Drug class | Small-molecule (non-peptide) GLP-1 agonist | Peptide GLP-1 agonist with SNAC absorption enhancer |
| Approved indication | Chronic weight management (obesity/overweight + comorbidity) | Chronic weight management + MACE reduction in established CV disease |
| Dosing timing | Any time, with or without food/water | Morning, empty stomach, ≤4 oz water, 30-min wait |
| Pivotal trial | ATTAIN-1 | OASIS 4 |
| Mean weight loss | 14.7-16.9% at 52 weeks (11.2% cited over 72 weeks in some analyses) | ~16.6% at 64 weeks |
| List price | $149-349/month self-pay | ~$1,349/month list |
| Lowest available price | $25/month with commercial insurance + savings card | Varies by insurance; savings cards available |
Weight loss figures are trial means and vary by individual. Always discuss expected outcomes with your healthcare provider.
Efficacy: How the Trial Numbers Compare
The efficacy case for each drug comes from separate Phase 3 programs rather than a true head-to-head trial, so comparisons should be read as directional rather than definitive.
In ATTAIN-1, Foundayo produced 14.7-16.9% mean weight loss at 52 weeks depending on dose, against 2.3% for placebo. Some FDA label analyses reference an 11.2% figure over a longer 72-week window, reflecting how the number can shift depending on the time point and dose analyzed. In OASIS 4, the Wegovy pill’s pivotal weight-loss trial, participants lost approximately 16.6% of body weight at 64 weeks.
On raw numbers, the Wegovy pill’s headline result sits at the higher end of Foundayo’s reported range. But because these come from different trials with different populations, durations, and designs, neither figure should be read as proof that one drug will outperform the other for a specific individual. Lilly’s ACHIEVE program, which is separately evaluating orforglipron in type 2 diabetes, has also produced head-to-head data against injectable comparators — but a formal randomized trial directly pitting Foundayo against the Wegovy pill for weight loss has not been published as of mid-2026.
Convenience: No Fasting vs. Strict Morning Rules
This is where the two drugs diverge most sharply in daily experience.
Foundayo is a small-molecule GLP-1 receptor agonist — chemically more like a conventional tablet (think ibuprofen) than a fragile peptide. Because it survives the digestive tract without needing a special coating or absorption enhancer, it carries no food or water restrictions. You can take it in the morning, at night, with breakfast, or on an empty stomach — whatever fits your schedule.
The Wegovy pill, by contrast, is built on the same peptide backbone as injectable semaglutide, made orally bioavailable through the SNAC (sodium N-the WeightLossInjections.com Staffcaprylate) absorption enhancer. Peptides are fragile and easily broken down by stomach acid and food, so the Wegovy pill must be taken first thing in the morning on an empty stomach with no more than 4 ounces of plain water, followed by a 30-minute wait before eating, drinking anything else, or taking other oral medications.
For people with unpredictable mornings, shift work, or difficulty remembering a strict pre-breakfast routine, this difference can matter as much as the efficacy numbers. For a deeper look at how timing affects adherence across all three oral GLP-1s, see our guide on oral GLP-1 pill timing.
Our Top 3 · August 2026
The best GLP-1 providers right now
Independently reviewed. Ranked by price, medication access, provider quality, and patient outcomes.
Renew GLP
Personalized GLP-1, GIP plans: Semaglutide & Tirzepatide.
Medvi
No membership or hidden fees. Everything you need is included.
Trimi
US-licensed clinicians and shipped to your door, from $99/mo.
Mechanism: Small Molecule vs. Peptide
The convenience gap traces directly back to how each drug is built.
- Foundayo (orforglipron): A first-in-class oral small-molecule, non-peptide GLP-1 receptor agonist developed under the code LY3502970. It activates the same GLP-1 receptor as peptide drugs but through a fundamentally different chemical structure that doesn’t require protection from stomach acid.
- Wegovy pill: Contains the same active peptide, semaglutide, found in Ozempic and injectable Wegovy, just at a much higher oral dose (25 mg) to compensate for how little of the peptide actually gets absorbed even with the SNAC enhancer.
This structural difference is also the likely explanation for the efficacy gap seen across trials: small-molecule GLP-1 agonism has, so far, tended to produce somewhat lower peak weight loss than the peptide-based approach, even though it wins decisively on dosing flexibility.
Cost Comparison
Pricing is one of the starkest differences between these two drugs.
| Payment scenario | Foundayo | Wegovy Pill |
|---|---|---|
| List price (no insurance) | $149-349/month | ~$1,349/month |
| With commercial insurance + savings card | As low as $25/month | Varies; manufacturer savings programs available |
| Medicare (Part D, GLP-1 Bridge, from July 1, 2026) | $50/month | Subject to standard Part D coverage rules |
Foundayo’s pricing structure, including the Medicare GLP-1 Bridge program, reflects Eli Lilly’s direct-to-consumer distribution strategy through LillyDirect, GoodRx, and major retail pharmacies. The Wegovy pill’s list price is closer to what’s typical for branded GLP-1 therapies before insurance or manufacturer savings programs are applied. For a full breakdown of pricing across all three oral GLP-1s, see our oral GLP-1 cost guide.
Side Effect Profiles
Both drugs belong to the same GLP-1 receptor agonist class and share the expected gastrointestinal side effect profile: nausea, vomiting, diarrhea, constipation, and decreased appetite, most pronounced during dose titration. Both carry the class boxed warning regarding thyroid C-cell tumors (medullary thyroid carcinoma) and are contraindicated in patients with a personal or family history of MTC or MEN 2 syndrome.
Foundayo’s trials additionally noted transaminase (liver enzyme) elevations warranting routine monitoring, without any unique gastrointestinal signal beyond the class norm. The Wegovy pill’s side effect profile mirrors that of other semaglutide products. Neither drug has shown a materially different overall safety signal from the other in published data so far. For more detail, see our guide on oral GLP-1 side effects.
Making the Trade-Off
Choosing between Foundayo and the Wegovy pill comes down to weighing a handful of trade-offs:
- If daily flexibility matters most to you — no fasting, no rigid morning window — Foundayo’s dosing profile is built for that.
- If you want the drug with the higher documented trial average and don’t mind a strict morning routine, the Wegovy pill’s OASIS 4 result is a relevant data point to discuss with your provider.
- If cost and insurance coverage are the deciding factor, Foundayo’s lower self-pay tiers and Medicare Bridge pricing may be more accessible, though actual out-of-pocket cost depends entirely on your specific plan.
Neither option is universally “better” — this is a decision to make with a healthcare provider who can weigh your health history, goals, and coverage.
FAQ
Is Foundayo or the Wegovy pill more effective for weight loss?
Based on separate trials, the Wegovy pill’s OASIS 4 result (~16.6% at 64 weeks) sits at the higher end of Foundayo’s ATTAIN-1 range (14.7-16.9% at 52 weeks, with some analyses citing 11.2% over 72 weeks). These come from different trial populations and durations, so they aren’t a direct head-to-head comparison. Your individual response may differ from either trial average.
Which is easier to take, Foundayo or the Wegovy pill?
Foundayo has no food, water, or timing restrictions and can be taken any time of day. The Wegovy pill must be taken in the morning on an empty stomach with minimal water and a 30-minute wait before eating or taking other medications, which many patients find more demanding.
Why is Foundayo so much cheaper than the Wegovy pill?
Foundayo’s self-pay pricing ($149-349/month) and insurance-assisted pricing (as low as $25/month) reflect Eli Lilly’s distribution strategy through LillyDirect and retail partners, plus a dedicated Medicare Bridge program. The Wegovy pill’s list price (~$1,349/month) is closer to typical branded GLP-1 pricing before insurance or savings cards are applied. Actual cost depends heavily on your specific insurance plan.
Can I switch from the Wegovy pill to Foundayo, or vice versa?
Switching between GLP-1 medications, including between two oral options, is a medical decision that depends on your current dose, response, and health history. Talk to your healthcare provider before making any change.
Are Foundayo and the Wegovy pill approved for the same thing?
Both are FDA-approved for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity. The Wegovy pill carries an additional approved indication for reducing major adverse cardiovascular events in people with established cardiovascular disease; Foundayo does not currently carry that indication.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Foundayo (orforglipron) and Wegovy pill (oral semaglutide 25 mg) are prescription medications with important safety information and contraindications. Discuss any medication decision with a qualified healthcare provider. Content published by WeightLossInjections.com, your complete resource for GLP-1 medications — injections and pills alike.
